Your browser doesn't support javascript.
loading
Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor α and Peroxisome Proliferator-Activated Receptor γ Coactivator 1α-Dependent Gene Expression to Increase Blood Triglyceride Levels.
Shizu, Ryota; Otsuka, Yuta; Ezaki, Kanako; Ishii, Chizuru; Arakawa, Shingo; Amaike, Yuto; Abe, Taiki; Hosaka, Takuomi; Sasaki, Takamitsu; Kanno, Yuichiro; Miyata, Masaaki; Yamazoe, Yasushi; Yoshinari, Kouichi.
  • Shizu R; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Otsuka Y; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Ezaki K; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Ishii C; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Arakawa S; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Amaike Y; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Abe T; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Hosaka T; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Sasaki T; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Kanno Y; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Miyata M; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Yamazoe Y; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
  • Yoshinari K; Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka,Suruga-ku, Shizuoka, Japan (R.S., K.E., Y.A., T.A., T.H., T.S., Y.K., K.Y.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan (Y.O., C.I., T.A., M.M., Y.Y., K.Y.); and Ph
Mol Pharmacol ; 98(5): 634-647, 2020 11.
Article en En | MEDLINE | ID: mdl-32892155
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Triglicéridos / Receptores Citoplasmáticos y Nucleares / PPAR alfa / PPAR gamma / Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma / Anticonvulsivantes Límite: Animals / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Triglicéridos / Receptores Citoplasmáticos y Nucleares / PPAR alfa / PPAR gamma / Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma / Anticonvulsivantes Límite: Animals / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article